Pharmacological strategies for the management of comorbid depression and schizophrenia

References

• Oosthuizen P, Emsley R, Niehaus D, et al. The relationships between depression and remission in first-episode psychosis. World Psychiatry. 2006;5(3):172–176.
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World federation of biological psychiatry (WFSBP) guidelines of biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16(3):142–170.
   PubMed Web of Science ®Google Scholar
• Conley RR, Ascher-Svanum H, Zhu B, et al. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007;90(1–3):186–197.
   PubMed Web of Science ®Google Scholar
• Upthegrove R, Birchwood M, Ross K, et al. The evolution of depression and suicidality in first episode psychosis. Acta Psychiatr Scand. 2010;122(3):211–218.
   PubMed Web of Science ®Google Scholar
• Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull. 2017;43(2):240–244.
   PubMed Web of Science ®Google Scholar
• Siris SG, Addington D, Azorin JM, et al. Depression in schizophrenia: recognition and management in the USA. Schizophr Res. 2001;47(2–3):185–197.
   PubMed Web of Science ®Google Scholar
• Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001;15(2):127–135.
   PubMed Web of Science ®Google Scholar
• Addington D, Addington J, Maticka-Tyndale E, et al. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6(3):201–208.
   PubMed Web of Science ®Google Scholar
• Stephens JH, Astrup C, Mangrum JC. Prognostic factors in recovered and deteriorated schizophrenics. Am J Psychiatry. 1966;122(10):1116–1121.
   PubMed Web of Science ®Google Scholar
• Resnick SG, Rosenheck RA, Lehman AF. An exploratory analysis of correlates of recovery. Psychiatr Serv. 2004;55(5):540–547.
   PubMed Web of Science ®Google Scholar
• Pompili M, Lester D, Innamorati M, et al. Assessment and treatment of suicide risk in schizophrenia. Expert Rev Neurother. 2008;8(1):51–74.
   PubMedGoogle Scholar
• Pompili M, Serafini G, Innamorati M, et al. Suicide risk in first episode psychosis: a selective review of the current literature. Schizophr Res. 2011;129(1):1–11.
   PubMed Web of Science ®Google Scholar
• van Rooijen G, van Rooijen M, Maat A, et al. Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling. Schizophr Res. 2019;208:82–89.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449.
   PubMed Web of Science ®Google Scholar
• Ceskova E, Prikryl R, Kasparek T, et al. One-year follow-up of patients with first-episode schizophrenia (comparison between remitters and non-remitters). Neuropsychiatr Dis Treat. 2007;3(1):153–160.
   PubMedGoogle Scholar
• Wasserman D, Rihmer Z, Rujescu D, et al. The European psychiatric association (EPA) guidance on suicides treatment and prevention. Eur Psychiatry. 2012;27(2):129–141.
   PubMed Web of Science ®Google Scholar
• Ceskova E, Prikryl R, Kasparek T. Suicides in males after the first episode of schizophrenia. J Nerv Ment Dis. 2011;199(1):62–64.
   PubMed Web of Science ®Google Scholar
• Birchwood M, Iqbal Z, Upthegrove R. Psychological pathways to depression in schizophrenia: studies in acute psychosis, post psychotic depression and auditory hallucinations. Eur Arch Psychiatry Clin Neurosci. 2005;255(3):202–212.
   PubMed Web of Science ®Google Scholar
• Müller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull. 2018;44(5):973–982.
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–1709.
   PubMed Web of Science ®Google Scholar
• Faugere M, Micoulaud-Franchi J-A, Faget-Agius C, et al. High C-reactive protein levels are associated with depressive symptoms in schizophrenia. J Affect Disord. 2018;225:671–675.
   PubMed Web of Science ®Google Scholar
• Fond G, Godin O, Schürhoff F. Inflammatory Depression advances in schizophrenia (IDEAS): A precision medicine approach of the national FACE-SZ cohort. J Affect Disord. 2019;245:468–474.
   PubMed Web of Science ®Google Scholar
• Rodrigues-Amorim D, Rivera-Baltanás T, Regueiro B, et al. The role of the gut microbiota in schizophrenia: current and future perspectives. World J Biol Psychiatry. 2018;19(8):571–585.
   PubMed Web of Science ®Google Scholar
• Harrow M, Yonan CA, Sands JR, et al. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull. 1994;20(2):327–338.
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 1: acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6(3):132–191.
   PubMed Web of Science ®Google Scholar
• Siris SG. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents. Am J Psychiatry. 2000;157(9):1379–1389.
   PubMed Web of Science ®Google Scholar
• Rybakowski JK, Vansteelandt K, Szafranski T, et al. Treatment of depression in first episode of schizophrenia: results from EUFEST. Eur Neuropsychopharmacol. 2012;22(12):875–882.
   PubMed Web of Science ®Google Scholar
• Riedel M, Mayr A, Seemüller F, et al. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. World J Biol Psychiatry. 2012;13(1):30–38.
   PubMed Web of Science ®Google Scholar
• Addington DE, Mohamed S, Rosenheck RA, et al. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry. 2011;72(1):75–80.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Corponi F, Fabbri C, Bitter I, et al. Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29:971–985.
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry. 2006;7(1):5–40.
   PubMed Web of Science ®Google Scholar
• Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(9):876–886.
   PubMed Web of Science ®Google Scholar
• Bartova L, Papageorgiou K, Milenkovic I, et al. Rapid antidepressant effect of S-ketamine in schizophrenia. Eur Neuropsychopharmacol. 2018;28(8):980–982.
   PubMed Web of Science ®Google Scholar
• van Rooijen G, Vermeulen JM, Ruhé HG, et al. Treating depressive episodes or symptoms in patients with schizophrenia. CNS Spectr. 2019;24(2):239–248.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56.
   PubMed Web of Science ®Google Scholar
• Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2004;65(2):177–186.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91.
   PubMed Web of Science ®Google Scholar
• Müller N. COX-2 inhibitors, aspirin, and other potential anti-inflammatory treatments for psychiatric disorders. Front Psychiatry. 2019;10:375.
   PubMed Web of Science ®Google Scholar
• Çakici N, van Beveren NJM, Judge-Hundal G, et al. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019;49(14):2307–2319.
   PubMed Web of Science ®Google Scholar
• Rao AV, Bested AC, Beaulne TM, et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009;1:1–6.
   PubMed Web of Science ®Google Scholar
• Dickerson FB, Stallings C, Origoni A, et al. Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Prim Care Companion CNS Disord. 2014;16(1):pii:PCC.13m01579.
   PubMedGoogle Scholar
• Severance EG, Gressitt KL, Stallings CR, et al. Probiotic normalization of candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study. Brain Behav Immun. 2017;62:41–45.
   PubMed Web of Science ®Google Scholar
• Cuomo A, Maina G, Rosso G, et al. The microbiome: a new target for research and treatment of schizophrenia and its resistant presentations? A systematic literature search and review. Front Pharmacol. 2018;9:1040.
   PubMed Web of Science ®Google Scholar
• Koga M, Serritella AV, Sawa A, et al. Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr Res. 2016;176(1):52–71.
   PubMed Web of Science ®Google Scholar
• Arroll MA, Wilder L, Neil J. Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J. 2014;13:91.
   PubMed Web of Science ®Google Scholar
• Ali SA, Mathur N, Malhotra AK, et al. Electroconvulsive therapy and schizophrenia: a systematic review. Mol Neuropsychiatry. 2019;5(2):75–83.
   PubMedGoogle Scholar
• Peng S, Li W, Lv L, et al. BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression. Discov Med. 2018;26(143):127–136.
   PubMed Web of Science ®Google Scholar
• Goud Alladi C, Etain B, Bellivier F, et al. DNA methylation as a biomarker of treatment response variability in serious mental illnesses: a systematic review focused on bipolar disorder, schizophrenia, and major depressive disorder. Int J Mol Sci. 2018;19(10):E3026.
   PubMed Web of Science ®Google Scholar
• Wium-Andersen IK, Vinberg M, Kessing LV, et al. Personalized medicine in psychiatry. Nord J Psychiatry. 2017;71:12–19.
   PubMed Web of Science ®Google Scholar
• Perna G, Grassi M, Caldirola D, et al. The revolution of personalized psychiatry: will technology make it happen sooner? Psychol Med. 2018;48:705–713.
   PubMed Web of Science ®Google Scholar
• Ceskova E. The need to improve current psychopharmacotherapy before developing new drugs. Expert Opin Pharmacother. 2014;15(14):1969–1973.
   PubMed Web of Science ®Google Scholar